The Chemotherapy Question Nobody Asked in Four Major Endometrial Cancer Trials
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
Checkpoint inhibitor combos are dominating oncology pipelines, but a structural gap between trial design and FDA approval pathways is...
OptiTROP-Lung05's HR of 0.35 over pembrolizumab monotherapy looks decisive, until you ask whether that comparator still reflects standard of...
VCN-01 plus gemcitabine/nab-paclitaxel improved OS in metastatic pancreatic cancer. The VIRAGE Phase 2b design shows what rigorous endpoint selection...
Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at the operational...
TALENTOP's phase 3 data shows liver resection after atezo-bev nearly doubles time to treatment failure in advanced HCC. The...
Merck and SCRI's Accelero™ collaboration targets community oncology enrollment, but the real test is whether 200+ sites can execute...
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...
ASCO and Ryght AI are using algorithms to select CDK4/6 inhibitor trial sites. Here's what ops teams need to...
The NordICC RCT cut colorectal cancer incidence but missed its mortality target — exposing a design flaw that should...